Merck has unveiled its investigational KRAS G12C inhibitor, calderasib, positioning it not merely as another potent molecule in a rapidly…
Read More

Merck has unveiled its investigational KRAS G12C inhibitor, calderasib, positioning it not merely as another potent molecule in a rapidly…
Read More